COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
Neurol Neuroimmunol Neuroinflamm
; 8(5)2021 09.
Article
em En
| MEDLINE
| ID: mdl-34429342
ABSTRACT
BACKGROUND AND OBJECTIVE:
To describe the impact of coronavirus disease 2019 (COVID-19) on people with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).METHODS:
The COVID-19 Infections in Multiple Sclerosis (MS) and Related Diseases (COViMS) Registry collected data on North American patients with MS and related diseases with laboratory-positive or highly suspected SARS-CoV-2 infection. Deidentified data were entered into a web-based registry by health care providers. Data were analyzed using t-tests, Pearson χ2 tests, or Fisher exact tests for categorical variables. Univariate logistic regression models examined effects of risk factors and COVID-19 clinical severity.RESULTS:
As of June 7, 2021, 77 patients with NMOSD and 20 patients with MOGAD were reported in the COViMS Registry. Most patients with NMOSD were laboratory positive for SARS-CoV-2 and taking rituximab at the time of COVID-19 diagnosis. Most patients with NMOSD were not hospitalized (64.9% [95% CI 53.2%-75.5%]), whereas 15.6% (95% CI 8.3%-25.6%) were hospitalized only, 9.1% (95% CI 3.7%-17.8%) were admitted to the ICU and/or ventilated, and 10.4% (95% CI 4.6%-19.5%) died. In patients with NMOSD, having a comorbidity was the sole factor identified for poorer COVID-19 outcome (OR = 6.0, 95% CI 1.79-19.98). Most patients with MOGAD were laboratory positive for SARS-CoV-2, and almost half were taking rituximab. Among patients with MOGAD, 75.0% were not hospitalized, and no deaths were recorded; no factors were different between those not hospitalized and those hospitalized, admitted to the ICU, or ventilated.DISCUSSION:
Among the reported patients with NMOSD, a high mortality rate was observed, and the presence of comorbid conditions was associated with worse COVID-19 outcome. There were no deaths reported in the patients with MOGAD, although these observations are limited due to small sample size.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sistema de Registros
/
Neuromielite Óptica
/
Doenças Autoimunes do Sistema Nervoso
/
Glicoproteína Mielina-Oligodendrócito
/
COVID-19
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article